검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Adalimumab Injection [Humira] |
Overview Company | AbbVie |
Overview Modality | ANTIBODY |
Overview Target | Mucopolysaccharidosis I |
Overview Indication | Mucopolysaccharidosis I; Mucopolysaccharidosis II |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | biomarker for adalimumab treatment of TNBC patients |
PK/PD Species | NHP, Mouse |
PK/PD Animal (cat.) | Human, Mouse, NHP, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | NHP, Mouse |
Toxicology Animal (cat.) | Human, Mouse, NHP, In vitro |
Toxicology Major finding | Recurrent acute bilateral cicatricial conjunctivitis as an adverse event of systemic adalimumab for rheumatoid arthritis.. Anti-TNF-α therapies, though known for their anti-inflammatory effects, have been associated with paradoxical inflammatory reactions, of which anterior uveitis is the most common. We report a case of recurrent bilateral cicatricial conjunctivitis linked to systemic adali… |
Clinical Data Tier / Score | A · 13 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Adalimumab Injection [Humira] |
Overview Company | AbbVie |
Overview Modality | ANTIBODY |
Overview Target | Mucopolysaccharidosis I |
Overview Indication | Mucopolysaccharidosis I; Mucopolysaccharidosis II |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | biomarker for adalimumab treatment of TNBC patients |
PK/PD Species | NHP, Mouse |
PK/PD Animal (cat.) | Human, Mouse, NHP, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | NHP, Mouse |
Toxicology Animal (cat.) | Human, Mouse, NHP, In vitro |
Toxicology Major finding | Recurrent acute bilateral cicatricial conjunctivitis as an adverse event of systemic adalimumab for rheumatoid arthritis.. Anti-TNF-α therapies, though known for their anti-inflammatory effects, have been associated with paradoxical inflammatory reactions, of which anterior uveitis is the most common. We report a case of recurrent bilateral cicatricial conjunctivitis linked to systemic adali… |
Clinical Data Tier / Score | A · 13 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교